These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

716 related items for PubMed ID: 18538401

  • 1. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
    Chan WM, Lai TY, Lai RY, Liu DT, Lam DS.
    Ophthalmology; 2008 Oct; 115(10):1756-65. PubMed ID: 18538401
    [Abstract] [Full Text] [Related]

  • 2. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study.
    Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS.
    Retina; 2008 Jan; 28(1):85-93. PubMed ID: 18185143
    [Abstract] [Full Text] [Related]

  • 3. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
    Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, Kang X, Liu Y, Yang L, Li Y, Zhou P, Pan CT, Zhang L, Liu P, Zhou H, Jiao X, Xiong Y, Tian R, Lu Y, Yu X, Li X.
    JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
    [Abstract] [Full Text] [Related]

  • 4. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M.
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [Abstract] [Full Text] [Related]

  • 5. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK, Chang CK, Peng CH.
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [Abstract] [Full Text] [Related]

  • 6. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
    Nicolò M, Zoli D, Musolino M, Traverso CE.
    Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
    [Abstract] [Full Text] [Related]

  • 7. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB, Mohr JK, Ossewaarde-van Norel A, den Hollander AI, Keunen JE, Hoyng CB, Boon CJ.
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [Abstract] [Full Text] [Related]

  • 8. Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).
    Lai TY, Wong RL, Chan WM.
    Trans Am Ophthalmol Soc; 2015 Mar; 113():T8. PubMed ID: 26755855
    [Abstract] [Full Text] [Related]

  • 9. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S.
    Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
    [Abstract] [Full Text] [Related]

  • 10. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.
    Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y, Wong TH.
    Ophthalmology; 2004 Aug; 111(8):1576-84. PubMed ID: 15288991
    [Abstract] [Full Text] [Related]

  • 11. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial.
    Wu ZH, Lai RY, Yip YW, Chan WM, Lam DS, Lai TY.
    Retina; 2011 Aug; 31(7):1378-86. PubMed ID: 21836413
    [Abstract] [Full Text] [Related]

  • 12. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH, Heo J, Kim C, Kim TW, Shin JY, Lee JY, Song SJ, Park TK, Moon SW, Chung H.
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [Abstract] [Full Text] [Related]

  • 13. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
    Liu Y, Li L, Xu G, Wang W.
    Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
    [Abstract] [Full Text] [Related]

  • 14. Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: five-year outcomes.
    Blasi MA, Tiberti AC, Scupola A, Balestrazzi A, Colangelo E, Valente P, Balestrazzi E.
    Ophthalmology; 2010 Aug; 117(8):1630-7. PubMed ID: 20417564
    [Abstract] [Full Text] [Related]

  • 15. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.
    Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS.
    Br J Ophthalmol; 2006 Jul; 90(7):869-74. PubMed ID: 16597666
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
    Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF.
    Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.
    Senturk F, Karacorlu M, Ozdemir H, Karacorlu SA, Uysal O.
    Am J Ophthalmol; 2011 Feb; 151(2):303-9.e1. PubMed ID: 21168824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.